Quoin Pharmaceuticals to Acquire 03 Life Sciences
Ticker: QNRX · Form: 8-K · Filed: Jan 16, 2025 · CIK: 1671502
| Field | Detail |
|---|---|
| Company | Quoin Pharmaceuticals, Ltd. (QNRX) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, pharmaceuticals
TL;DR
Quoin is buying 03 Life Sciences, deal expected to close Q1 2025.
AI Summary
Quoin Pharmaceuticals, Ltd. announced on January 14, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of 03 Life Sciences. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions. This acquisition aims to expand Quoin's product pipeline and market reach.
Why It Matters
This acquisition could significantly expand Quoin Pharmaceuticals' product offerings and market presence in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and potential failure to achieve expected synergies.
Key Players & Entities
- Quoin Pharmaceuticals, Ltd. (company) — Acquiring company
- 03 Life Sciences (company) — Target company
- January 14, 2025 (date) — Date of agreement
- first quarter of 2025 (date) — Expected closing period
FAQ
What is the primary purpose of Quoin Pharmaceuticals acquiring 03 Life Sciences?
The acquisition is intended to expand Quoin's product pipeline and market reach.
When is the acquisition of 03 Life Sciences expected to be completed?
The transaction is expected to close in the first quarter of 2025.
What are the conditions for the closing of the acquisition?
The closing is subject to customary closing conditions.
What was Quoin Pharmaceuticals' former name?
Quoin Pharmaceuticals, Ltd. was formerly known as Cellect Biotechnology Ltd. and Cellect Biomed Ltd.
What is the principal executive office address for Quoin Pharmaceuticals?
The principal executive offices are located at 42127 Pleasant Forest Court, Ashburn, VA 20148-7349.
Filing Stats: 591 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-01-16 16:30:24
Filing Documents
- tm253523d1_8k.htm (8-K) — 25KB
- 0001104659-25-004132.txt ( ) — 193KB
- qnrx-20250114.xsd (EX-101.SCH) — 3KB
- qnrx-20250114_lab.xml (EX-101.LAB) — 33KB
- qnrx-20250114_pre.xml (EX-101.PRE) — 22KB
- tm253523d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. Quoin Pharmaceuticals Ltd. (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced on January 14, 2025 further positive clinical data from its ongoing pediatric Netherton Syndrome study. After six weeks of dosing in Quoin's ongoing 12-week Investigator Pediatric Study, a significant improvement was observed in the skin area treated with QRX003 versus the non-treated area. Specifically, at baseline prior to dosing with QRX003, the IGA assessment of the subject's skin was classified as severe.' After 12 days of dosing, the IGA assessment of the subject's skin was classified as "mild-moderate." Now, after six weeks of dosing twice a day, the IGA assessment of the subject's skin was classified as "Mild." As a result of these positive results, the subject is being transitioned to having QRX003 applied to their whole body surface area (BSA) as opposed to the approximately 20% of their BSA that was being tested for the initial six weeks. In addition, there have been no adverse events or safety concerns reported to date for this subject, which is consistent with observations from each of Quoin's ongoing clinical studies in Netherton Syndrome
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Date: January 16, 2025 QUOIN PHARMACEUTICALS LTD. By: /s/ Michael Myers Name: Dr. Michael Myers Title: Chief Executive Officer